SEARCH:   Advanced

Blood, 15 May 2006, Vol. 107, No. 10, pp. 4030-4038. Prepublished online as a Blood First Edition Paper on January 17, 2006; DOI 10.1182/blood-2005-10-4239. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-10-4239v1 107/10/4030    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ortonne, N. Articles by Bensussan, A. Search for Related Content PubMed PubMed Citation Articles by Ortonne, N. Articles by Bensussan, A. Related Collections Immunobiology Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Significance of circulating T-cell clones in Sézary syndrome Nicolas Ortonne, Delphine Huet, Caroline Gaudez, Anne Marie-Cardine, Valérie Schiavon, Martine Bagot, Philippe Musette, and Armand Bensussan From the Institut National de la Santé et de la Recherche Médicale (INSERM) Unit 659, Faculté de Médecine de Créteil, Créteil, France; Department of Pathology, Hôpital Henri Mondor, Créteil, France; INSERM Unit 532, Hôpital Saint Louis, Paris, France; Department of Dermatology, Hôpital Henri Mondor, Créteil, France; INSERM Unit 519, Faculté de Médecine de Rouen, Rouen, France; and Department of Dermatology, CHU de Rouen, Rouen, France. Identification of malignant Sézary cells by T-cell receptor (TCR) clonality studies is routinely used for the diagnosis of Sézary syndrome, but T-cell clones expressed in a single patient have never been accurately characterized. We previously reported that CD158k expression delineates Sézary syndrome malignant cells, and, more recently, we identified vimentin at the surface membranes of Sézary cells and normal activated lymphocytes. In the present study, T-cell clones from 13 patients with Sézary syndrome were identified by immunoscopy and further characterized in the blood according to their TCR V, CD158k, and vimentin cell-surface expression. We found in most patients a unique malignant T-cell clone that coexpressed CD158k and vimentin and that, when patients were tested, was also present in the skin. However, in some patients we detected the presence of a nonmalignant circulating clone expressing high amounts of vimentin and lacking CD158k. These results indicate that clonal expansion may originate from circulating malignant and nonmalignant CD4+ T cell populations in patients with Sézary syndrome. Identification of the malignant cells in Sézary syndrome cannot be achieved by T-cell clonality studies or by TCR V monoclonal antibody (mAb) analysis alone; it also relies on CD158k phenotyping. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Marie-Cardine, D. Huet, N. Ortonne, N. Remtoula, S. L. Gouvello, M. Bagot, and A. Bensussan Killer cell Ig-like receptors CD158a and CD158b display a coactivatory function, involving the c-Jun NH2-terminal protein kinase signaling pathway, when expressed on malignant CD4+ T cells from a patient with Sezary syndrome Blood, June 1, 2007; 109(11): 5064 - 5065. [Full Text] [PDF] S. Hahtola, S. Tuomela, L. Elo, T. Hakkinen, L. Karenko, B. Nedoszytko, H. Heikkila, U. Saarialho-Kere, J. Roszkiewicz, T. Aittokallio, et al. Th1 Response and Cytotoxicity Genes Are Down-Regulated in Cutaneous T-Cell Lymphoma. Clin. Cancer Res., August 15, 2006; 12(16): 4812 - 4821. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020